| Share Price | 2,155.00p | Close | 2,155.00p |
| Change Today | 20.00p | Volume | 1,518,895 |
| Percent Change | 0.94 % | Day High / Low | 2,160.00p / 2,114.00p |
| Update Time | 20:31:04 | Year High / Low | 2,160.00p / 1,727.00p |
| Bid | 2,083.00p | Last Trade Price | 2,155.00p |
| Offer | 2,175.00p | Last Trade Amount | 13,702 |
| Open | 2,132.00p | Last Trade Time | 16:43:40 |
| Period | Price | Change | Percent Change |
|---|---|---|---|
| 1 week | 2,040.00p | +115.00p | +5.64% |
| 1 month | 1,982.00p | +173.00p | +8.73% |
| 3 months | 2,096.00p | +59.00p | +2.81% |
| 6 months | 1,796.00p | +359.00p | +19.99% |
| 1 year | 1,928.00p | +227.00p | +11.77% |
| Ex-Marker Code | Ex-Dividend | NMS | 1,000 |
| Ex-Marker Start | 06-Mar-13 | VWAP | 2,139.18p |
| Ex-Marker End | 09-Apr-13 | Beta | 0.78 |
| Index / Sector | Value | Change | Percent Change |
|---|---|---|---|
| FTSE 100 | 6,840.27 | +36.40 | +0.54% |
| FTSE 350 | 3,678.09 | +17.49 | +0.48% |
| FTSE All-Share | 3,604.73 | +16.88 | +0.47% |
| FTSEurofirst 300 | 1,256.28 | +5.66 | +0.45% |
| Pharmaceuticals & Biotechnology | 11,857.49 | +225.03 | +1.93% |
| techMARK | 2,572.42 | +7.61 | +0.30% |
| techMARK 100 | 2,932.12 | +4.88 | +0.17% |
| Currency | UK Pounds |
| Share Price | 2,155.00p |
| Change Today | 20.00p |
| % Change | 0.94 % |
| 52 Week High | 2,160.00 |
| 52 Week Low | 1,727.00 |
| Volume | 1,518,895 |
| Shares Issued | 554.09m |
| Market Cap | £11,941m |
| Beta | 0.78 |
| RiskGrade | 130 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 20 |
| Buy | 2 |
| Neutral | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 28 |

| Latest | Previous | |
|---|---|---|
| 2nd Interim | Interim | |
| Ex-Div | 06-Mar-13 | 05-Sep-12 |
| Paid | 09-Apr-13 | 04-Oct-12 |
| Amount | 14.60¢ | 2.73¢ |
| Time | Volume / Share Price |
| 16:43 | 13,702 @ 2,155.00p |
| 16:42 | 6,000 @ 2,153.00p |
| 16:42 | 16,452 @ 2,128.40p |
| 16:42 | 6,000 @ 2,133.00p |
| 16:35 | 152 @ 2,155.00p |
| Chair | Matthew Emmens |
| CEO | Angus Russell |
| CFO | Graham Hetherington |
| CEO | Flemming Ornskov |
You are here: research